It generally is accepted that earlier diagnosis of sarcoma is associated with a better disease-free survival. Because the legal community is convinced this is true, a delay in cancer diagnosis is a frequent source of medical malpractice lawsuits. We asked whether symptom duration before diagnosis affected sarcoma outcome. We compiled prospective data from 624 consecutive patients with sarcoma treated from 1992 to 2003. The data included length of symptoms before diagnosis, tumor size and grade, presence of metastatic disease at diagnosis, anatomic location, disease-free survival, overall survival, and local recurrence. Length of symptoms did not predict presence of metastatic disease at diagnosis, survival, or disease-free survival. We found no correlation between the length of a patient's symptoms and the tumor size or anatomic site of disease (axial, proximal, and distal). Tumors were larger at diagnosis in axial and proximal locations than in more peripheral locations, despite no difference in length of symptoms before diagnosis. Patients with sarcoma with long-standing symptoms did not have a worse prognosis than those with a shorter length of symptoms before diagnosis in terms of disease-free survival, overall survival, and presence of metastatic disease at diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.